## Clinical Outcomes of Liver Transplant for Unresectable Colorectal Liver Metastasis



## **ARTx-Onc**: American Registry for Transplant Oncology

## Dear ASTS Member,

Liver transplantation for unresectable colorectal liver metastasis (CRLM) has steadily increased in the United States and Canada over the past 5 years. A recent analysis reported 46 transplanted patients since 2018,¹ while an estimated 165,000 new cases of metastatic colorectal cancer were diagnosed in the US.² Selection for these patients are center specific and not standardized and currently there is not a central repository of transplant and oncologic outcomes for these patients.

With the endorsement of The American Society of Transplant Surgeons, the University of Rochester Division of Transplantation have established a registry of patients with unresectable colorectal liver metastasis treated with liver transplantation. Because of your clinical and academic experience in the field of transplantation and colorectal liver metastases, we would like to invite you to collaborate in **ARTx-Onc**.

Our goal is to understand the transplant and oncologic outcomes of these patients, based on center specific selection criteria. We will analyze patient survival, oncologic recurrence and clinical outcomes. This will ultimately lead to development of national guidelines and selection criteria that we will publish as a group.

The University of Rochester Medical Center (URMC) Division of Transplantation will serve as primary registry management team. The registry will collect multi-institutional, de-identified data from retro and prospective studies. Our team will maintain the database and ensure data completeness. URMC will serve as the central IRB for data analysis and organizer of data use agreements (DUAs). Individual centers will need their own IRB for data collection. After IRB and DUA completion, data can be uploaded to our REDCap. For access, please fill out the form on the following link:

Scientific analysis of this registry will be conducted with all contributors who will be granted group authorship. The **ARTx-Onc** team is dedicated to sufficient power in publication and will plan for data analysis and publication after sufficient data has been uploaded to the registry.

https://www.urmc.rochester.edu/surgery/research/american-registry-for-transplant-oncology.aspx

1. Sasaki K, Ruffolo LI, Kim MH, et al. The Current State of Liver Transplantation for Colorectal Liver Metastases in the United States: A Call for Standardized Reporting. *Annals of Surgical Oncology*. 2023;30(5):2769-2777. doi:10.1245/s10434-023-13147-6

2. Board CNE. Colorectal Cancer - Statistics. Cancer.Net. Accessed April, 2023. https://www.cancer.net/cancer-types/colorectal-cancer/statistics

## **Executive Committee**

Talia Baker, M.D., *University of Utah* 

Chair, ASTS Liver Oncology Task Force

Elizabeth Pomfret, M.D., Ph.D. University of Colorado

President, ASTS

William Chapman, M.D., Washington University

Past-President, ASTS

Roberto Hernandez Alejandro, M.D., University of

Rochester

Principal Investigator, LT for CRLM

Registry Team, *University of Rochester*Matt Byrne, M.D. - Registry Manager
M. Katherine Dokus, M.P.H. - Data Integrity
John Martens, M.P.H.- Data Integrity
Mariana Chavez-Villa, M.D. – Scientific Officer
Luis Ruffolo, M.D. – Scientific Officer

